NRG ONCOLOGY STUDY BN007: RANDOMIZED PHASE II/III TRIAL OF IPILIMIUMAB (IPI) PLUS NIVOLUMAB (NIVO) VS. TEMOZOLOMIDE (TMZ) IN MGMT-UNMETHYLATED (UMGMT) NEWLY DIAGNOSED GLIOBLASTOMA (NGBM) Other Scholarly Work

Lassman, AB, Polley, MC, Iwamoto, FM et al. (2023). NRG ONCOLOGY STUDY BN007: RANDOMIZED PHASE II/III TRIAL OF IPILIMIUMAB (IPI) PLUS NIVOLUMAB (NIVO) VS. TEMOZOLOMIDE (TMZ) IN MGMT-UNMETHYLATED (UMGMT) NEWLY DIAGNOSED GLIOBLASTOMA (NGBM) . NEURO-ONCOLOGY, 25 10.1093/neuonc/noad137.005

Open Access

cited authors

  • Lassman, AB; Polley, MC; Iwamoto, FM; Sloan, AE; Wang, TJC; Aldape, KD; Wefel, JS; Gondi, V; Gutierrez, AN; Manasawala, M; Gilbert, MR; Sulman, EP; Wolchok, JD; Greene, RM; Neil, EC; Lukas, RV; Goldlust, SA; Snuderl, M; Dignam, JJ; Won, M; Movsas, B; Mehta, MP

authors

publication date

  • September 1, 2023

published in

keywords

  • Clinical Neurology
  • Life Sciences & Biomedicine
  • Neurosciences & Neurology
  • Oncology
  • Science & Technology

Location

  • NETHERLANDS, Rotterdam

Digital Object Identifier (DOI)

publisher

  • OXFORD UNIV PRESS INC

volume

  • 25